Mario P. Colombo

TL;DR: The authors identify the challenges and proposed set of minimal reporting guidelines for mouse and human MDSC are a heterogeneous population expanded in cancer and other chronic inflammatory conditions.

TL;DR: These suppressor cells challenge the current idea that tumor-conditioned immunosuppressive monocytes/macrophages are alternatively activated and show how the inflammatory response elicited by tumors had detrimental effects on the adaptive immune system and suggest novel approaches for the treatment of tumor-induced immune dysfunctions.

TL;DR: This report continued a series of recent articles published in Cancer Research, which provided strong evidence that antigen-specific immunosuppression by Gr-1+CD11b+ myeloid cells, which was mediated by the expression of CD80, is real.

TL;DR: Excessive clinical toxicity and modest clinical response observed in the clinical trials point to the necessity to plan protocols that minimize toxicity without affecting the anti-tumor effect of IL-12.

TL;DR: Results indicate that effector cells can be recruited and activated in vivo by antigen-pulsed DC, providing an efficient immune reaction against tumors, and that a long- lasting immunity against tumor challenge can be induced using beta-gal- pulsed bm-DC as vaccine.